Skip to Content

Teleflex Inc TFX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Teleflex Still Tracking Below Baseline, Recovery Underway, but Still a Ways to Go; Maintain FVE

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Teleflex had a mixed fourth quarter with sales across most product lines still below a prepandemic baseline, though the firm had some pockets of relative strength in vascular access and interventional urology. We are maintaining our $192 fair value estimate and no-moat rating, and shares remain overvalued, in our view.

Read Full Analysis

Company Profile

Business Description

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (23% of sales), interventional (17%), surgical (14%), anesthesia (13%), interventional urology (11%), original-equipment manufacturing (10%), and all other (12%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

Contact
550 East Swedesford Road, Suite 400
Wayne, PA, 19087
T +1 610 225-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 14,000